---
audienceLevel: patient
cancerTypes:
- general
citation: NCI, 2025
language: en
lastReviewed: '2025-12-30'
license: public_domain
reviewFrequency: quarterly
source: NCI
sourceType: 02_nci_core
status: active
tags:
- treatment
title: ADE - NCI
url: https://www.cancer.gov/about-cancer/treatment/drugs/ade
version: v1
---

# ADE - NCI

# ADE

This chemotherapy combination contains the drugs cytarabine (Ara-C), daunorubicin hydrochloride, and etoposide phosphate. Combinations usually work better than single drugs because
different drugs kill
cancer
cells in different ways.

Drugs in the ADE combination:

|  |  |
| --- | --- |
| **A** | = [Cytarabine](/about-cancer/treatment/drugs/cytarabine) (Ara-C) |
| **D** | = [Daunorubicin Hydrochloride](/about-cancer/treatment/drugs/daunorubicinhydrochloride) |
| **E** | = [Etoposide Phosphate](/about-cancer/treatment/drugs/etoposidephosphate) |

Each of the
drugs
in this
combination
is approved by the
[Food and Drug
Administration (FDA)](/Common/PopUps/popDefinition.aspx?id=454785&version=Patient&language=English)
to treat cancer or conditions related to
cancer.

## Use in Cancer

ADE is used to treat:

- **[Acute myeloid leukemia](/Common/PopUps/popDefinition.aspx?id=46347&version=Patient&language=English)** in children.

This combination may also be used with other drugs or treatments or to treat other types of cancer.

## More About ADE

[Definition from the NCI Drug Dictionary](https://www.cancer.gov/publications/dictionaries/cancer-drug/def/656988) - Detailed scientific definition and other names for this drug.
